ClinicalTrials.gg
RecruitingNCT07208591Updated Jan 2, 2026

To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome

A Phase 3 interventional study of STSA-1002 injection and STSA-1002 Injection Placebo in Acute Respiratory Distress Syndrome (ARDS), sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd. Recruiting at 15 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
406
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.

Planned enrollment
12th of 81
406 · median 100
Started
2025
with 12 others
Phase 3
5 of 146
4 open now
Primary completion
2026-07
later than 22 of 54 live
Registered
123rd of 146
by date

Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 12th largest by planned enrollment of the 81 interventional ones that give a count, is one of 13 that started in 2025, is one of 5 in phase 3, reaches primary completion later than 22 of the 54 other live ones, and was the 123rd registered.

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 282 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Respiratory Distress Syndrome with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy, safety and tolerability of STSA-1002 injection in patients with acute respiratory distress syndrome

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ ≤ 85 years old;
  2. laboratory tests results indicate respiratory viral infection;
  3. Fulfills the diagnostic criteria for A New Global Definition of Acute Respiratory Distress Syndrome ;
  4. The time from the onset of respiratory infection-related symptoms to randomization is ≤ 12 days (for patients without invasive mechanical ventilation)/)/≤ 14 days (for patients with invasive mechanical ventilation); Or worsening of respiratory infection-related symptoms within ≤7 days from randomization;
  5. PaO2/FiO2≤200mmHg;
  6. The subjects (including their partners) have no plans to have children during the trial and within 3 months after the last dose, and agree to take appropriate and effective measures (such as contraceptive pills, condoms, etc.);
  7. Volunteer to participate in the trial and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. ECMO before the first dose;
  2. According to the comprehensive judgment of the investigator, the patient's condition improved within 48 hours before the first dose;
  3. The expected survival period is no more than 24 hours or cardiac arrest occurred 4 weeks before the first dosedose;
  4. Patients with stroke or acute coronary syndrome within 3 months before randomization;
  5. Patients with cardiogenic pulmonary edema, which is the main cause of respiratory failure; New York Heart Classification III-IV patients;
  6. Severe chronic respiratory failure;
  7. Known active pulmonary tuberculosis;
  8. Combined with liver insufficiency
  9. Long-term dialysis and/or known severe renal impairment Cytomegalovirus infection;
  10. Known infection with \< 200 cells/μL;
  11. Organ transplant patients;
  12. Patients who received radiotherapy and chemotherapy in the past 1 years or the malignant tumor is still in the active phase;
  13. Septic shock
  14. is less than 0.5×109/L;
  15. is less than 60g/L, or the researcher judges that there is active gastrointestinal bleeding;
  16. Severe underlying diseases with poor compliance with basic treatment;17. Pregnant or lactating women;

18. Participated in new drug clinical trials and medication within 3 months before screening; 19. Allergic or allergic to any component of the trial drug and its (such as allergic to two or more drugs); 20. Other diseases or conditions that the investigator considers unsuitable for participation in this trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
406 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Patients in this group will receive basal treatment and STSA-1002.

    Drug: STSA-1002 injection

  • Placebo comparator
    Placebo group

    Patients in this group will receive basal treatment and STSA-1002.

    Drug: STSA-1002 Injection Placebo

Interventions

  • basal treatment + STASA-1002 intravenous infusion

  • DrugSTSA-1002 Injection Placebo

    basal treatment + STSA-1002 Injection Placebo

06

What researchers measure

Primary outcomes

  1. 28-day all-cause mortality rate

    Time frame: Day28 after first dose

Secondary outcomes

  1. 60-day all-cause mortality rate

    Time frame: Day60 after first dose

  2. Proportion of subjects with a decrease in the level of respiratory support on Day 28

    Time frame: Day28 after first dose

  3. ICU length of stay and total hospitalization time on Day 28

    Time frame: Day28 after first dose

  4. Proportion of subjects with PaO2/FiO2 > 300 mmHg or free of respiratory support on Day 28

    Time frame: Day28 after first dose

  5. Days alive without invasive mechanical ventilation

    Time frame: Day28 after first dose

  6. Changes in SOFA values from baseline on Day 3, 7, 10, and 14

    Time frame: Day14 after first dose

07

Study locations

15 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2026, 9 months after the start.

Of 39 phase 3 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2025
First posted
Oct 6, 2025
StartActual
Oct 31, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Oct 2026
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07208591
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Oct 31, 2025
Primary completion
Jul 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jan 2, 2026

Study contacts

Aiping Sun
Contact
sunaiping@staidson.com
+8618611103198
Bin M.D. Cao
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Greziprubart

Start the discussion